首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

2126366

發炎相關生物標記市場：策略性洞察與預測（2026-2035）

Inflammation-related Biomarkers Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計發炎相關生物標記市場將從 2026 年的 74.4 億美元成長到 2035 年的 185.1 億美元，複合年成長率為 10.7%。

發炎相關生物標記市場正經歷著顯著的變革，這主要得益於精準醫療模式轉移以及人們日益認知到慢性發炎是多種疾病的根本原因。這一市場演變的特點是，對能夠支持診斷、預後和治療監測的客觀生物指標的需求不斷成長，這些指標涵蓋了包括自體免疫疾病、腫瘤、心血管疾病和感染疾病在內的多個治療領域。多重生物標記平台、次世代定序和質譜等先進分析平台的整合，使得人們能夠更全面地了解複雜的發炎路徑。隨著自體免疫和慢性發炎性疾病的盛行率持續上升，醫療專業人員正在尋求客觀的工具來評估疾病活動度和治療效果。製藥公司正在加強生物標記的整合，因為可測量的生物反應指標對於療法的開發至關重要。監管機構也日益認知到，發炎相關生物標記是支持疾病診斷、治療研發和精準醫療策略的關鍵工具。市場正在對多體學方法、細胞激素分析和人工智慧驅動的生物標記發現進行大量投資，而發炎相關生物標記被定位為全球醫療保健機構精準醫療的核心要素。

市場促進因素

自體免疫疾病和慢性發炎性疾病（CIRs）負擔的日益加重是發炎自體免疫生物標記市場的主要驅動力。由於持續性發炎會導致疾病進展和長期併發症，這些疾病構成了重大的醫療保健挑戰。隨著醫療專業人員尋求客觀方法來評估疾病活動度和治療效果，對發炎相關生物標記的需求不斷成長。這種需求促使診斷開發商提高生物標記的敏感度和臨床相關性。行業相關人員正在擴大生物標記開發項目，以滿足不斷變化的臨床需求。因此，發炎生物標記檢測在醫療保健系統中的應用正在加速，發炎相關生物標記的應用也在穩步擴展。精準醫療和標靶治療的擴展透過對生物學表徵的需求進一步加速了市場成長。精準醫療依賴生物指標來支持個人化的治療決策。隨著醫療專業人員越來越需要有關免疫活性和治療反應的患者特異性信息，對發炎生物標記的需求也在不斷成長。這一趨勢凸顯了不考慮生物學變異性的通用治療方法的限制。為了改善個人化醫療，各機構正加強研究和檢驗生物標記。因此，基於生物標記的治療策略正得到更廣泛的應用。生物標記在藥物研發中的日益普及，推動了其在整體藥物研發領域的應用擴展。藥物研發依賴可測量的生物學終點，這些終點能夠揭示治療效果和作用機制。隨著製藥公司尋求治療反應和患者分層的早期指標，對發炎相關生物標記的需求日益成長。這項挑戰凸顯了能夠簡化臨床試驗和監管申報流程的生物標記的重要性。各機構正將發炎生物標記納入其研發項目，以改善藥物生命週期中的決策。多重和多組體學技術的進步正透過科學進步加速市場發展。現代生物標記發現需要能夠評估複雜生物相互作用的技術。由於發炎路徑涉及多種相互關聯的細胞和分子機制，因此對精密分析平台的需求日益成長。

市場限制因素

由於發炎反應在不同患者、疾病和臨床環境中差異顯著，檢驗生物標記仍然是一項極具挑戰性的任務。發炎的生物學變異性使得對生物標記的解讀難以保持一致。由於不同實驗室和醫療系統在調查方法和分析平台方面存在差異，標準化挑戰仍然存在。缺乏統一的方案降低了可比性和臨床可靠性。實施先進的分子和多重分析技術的高昂成本繼續限制了其在資源匱乏環境中的應用。先進平台所需的大量資金投入對小規模機構而言是一個障礙。數據整合和解讀的挑戰進一步增加了多參數生物標記分析的複雜性。

對技術和生物標記類型的深入了解

技術發展趨勢的特徵是多重生物標記平台和整合多組學方法的重要性日益凸顯。由於發炎性疾病涉及眾多相互關聯的生物介質，而單一標記方法無法充分錶徵這些介質，因此對多重體學平台的需求不斷成長。這種複雜性進一步凸顯了免疫檢測、流式細胞技術、PCR 和 NGS 技術的作用，這些技術能夠提供多維度的生物學見解。免疫分析仍然是檢測標靶蛋白生物標記的關鍵方法。免疫檢測分析在綜合蛋白質體學分析的應用日益廣泛。片段分析表明，隨著對免疫介導疾病中發炎訊號通路動態評估的日益重要，對細胞激素和趨化素生物標記的需求正在增加。包括 CRP 在內的急性期蛋白生物標記繼續支持發炎的常規臨床評估。細胞發炎生物標記能夠揭示免疫細胞的參與情況。遺傳和基因組發炎生物標記在患者分層和精準醫療中的應用正在不斷擴展。由於發炎路徑涉及多種相互關聯的生物訊號，多生物標記檢測組合的應用日益廣泛。自體免疫疾病是其主要應用領域之一，治療決策越來越依賴免疫活性的生物學特徵分析。腫瘤學、心血管疾病、感染疾病、神經系統疾病和代謝性疾病也是重要且快速成長的應用領域。醫院和臨床檢查室是主要的終端用戶，製藥和生物技術公司也不斷擴大生物標記的應用範圍。在發炎生物標記研究中，人工智慧的整合變得日益重要，因為它會產生複雜的資料集，需要先進的分析能力。各機構正在採用機器學習技術來改善生物標記的發現和臨床解讀。

競爭格局與策略展望

在競爭激烈的市場格局中，除了成熟的生命科學和診斷公司外，專注於生物標記、分析和精準醫療的供應商也加入了競爭。賽默飛世爾科技憑藉其廣泛的分析儀器、免疫檢測、分子生物學工具和主導研究解決方案產品組合，保持領先地位。這些產品組合支援整個生物標記開發流程，並擴展了整合的研究和診斷能力，以應對生物標記發現和檢驗日益複雜的挑戰。羅氏則透過整合藥物開發、伴隨診斷和精準醫療計劃而脫穎而出，並在免疫學、腫瘤學和慢性病管理領域拓展了以生物標記為驅動的醫療保健項目。丹納赫憑藉其子公司提供支持生物標記發現、分子分析和轉化研究的技術，佔據著重要的市場地位，並透過持續投資診斷和生命科學領域來加強創新。 Bio-Rad憑藉其支持分析方法開發、生物標記定量和轉化研究活動的技術，仍然是行業中的關鍵參與者，並透過持續的技術改進和流程最佳化來擴展其分析能力。 QIAGEN 的分子診斷和檢體分析技術持續支持以生物標記主導的醫療保健方法，並不斷擴展其分子分析能力以滿足精準醫療和轉化研究日益成長的需求，因此其戰略地位依然舉足輕重。 Agilent 透過其分析技術為市場提供支持，這些技術能夠利用代謝體學、蛋白質組學和基因組學進行生物標記的表徵和研究，並不斷加強其創新承諾，以提高分析性能和研究效率。 Illumina 則憑藉其在定序技術領域的領先地位脫穎而出，這些技術支持基因組和轉錄組生物標記的發現。每家公司都在致力於透過多重生物標記檢測、多體學平台和人工智慧驅動的發現工具的創新來擴展產品系列。在生物標記發現和檢驗需求的驅動下，診斷製造商、製藥公司和研究機構之間的策略合作夥伴關係正在不斷加強。地理擴張仍然是關鍵的策略重點，每家公司都將目光投向了快速成長的亞太地區和醫療基礎設施不斷完善的新興市場。

簡明結論

發炎相關生物標記市場預計將持續成長，這主要得益於慢性疾病負擔、精準醫療和技術創新三者共同推動的趨勢。從單一生物標記檢測轉向整合多組體學和多重檢測平台，標誌著醫療保健領域的根本性變革。儘管生物標記的檢驗、標準化和部署成本方面仍存在挑戰，但對技術、夥伴關係和證據產生的策略性投資正為市場領導提供持續的競爭優勢。長期市場前景仍然樂觀，發炎相關生物標記正從以研究為中心的領域發展成為精準醫療的核心要素，為全球醫療保健系統的診斷、治療最佳化和療法開發提供支持。

本報告的主要益處

深入分析：對各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業部門進行詳細的市場洞察。
競爭格局：了解主要參與者的策略舉措，並確定最佳的市場進入方式。
市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
實用建議：我們支援制定策略決策以開發新的收入來源。
適合各類讀者：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

公司對我們報告的使用

產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發和競爭情報。

調查範圍

歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期為 2026 年至 2035 年。
成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
競爭對手定位、策略、市場佔有率評估和貿易分析
細分市場和區域銷售成長及預測評估
公司簡介，包括策略、產品、財務狀況和主要發展動態。

市場定義和範圍
行業概覽
產業變化
主要市場趨勢
市場規模表現分析
市場預測分析
疾病負擔與未滿足的需求
發炎相關疾病的流行病學和盛行率分析
已確診患者族群的分析
測試數量分析
生物標記在臨床和研究領域的應用
發炎生物標記在精準醫學中的作用

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新型生物標記發現技術
產品創新與檢測方法開發
臨床試驗分析
管道分析
生物標記研究中的多體學整合
人工智慧驅動的生物標記識別與檢驗
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章：發炎相關生物標記市場：展望分析

分析：依生物標記類型
分析：按技術平台
分析：依樣本類型
分析：透過臨床應用
分析：透過調查方法

第9章：發炎相關生物標記市場：細分市場分析

依生物標誌類型
- 細胞激素生物標記
- 趨化素生物標記
- 急性期蛋白生物標記物
- 細胞發炎生物標記
- 遺傳和基因組發炎生物標記物
- 多生物標記檢測
透過技術平台
- 免疫測量
- 流式細胞技術
- 聚合酵素鏈鎖反應（PCR）
- 次世代定序（NGS）
- 質譜分析
- 多重生物標記平台
臨床應用
- 自體免疫疾病
- 腫瘤學
- 心血管疾病
- 感染疾病
- 神經病變
- 代謝性疾病
最終用戶
- 醫院和臨床檢查室
- 學術研究機構
- 製藥和生物技術公司
- 受託研究機構

第10章：發炎相關生物標記市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：發炎相關生物標記市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
日本
中國
印度
韓國
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd
Danaher Corporation
Bio-Rad Laboratories, Inc.
QIAGEN NV
Agilent Technologies, Inc.
Revvity, Inc.
Illumina, Inc.
Standard BioTools Inc.
Olink Holding AB
Bio-Techne Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
NeoGenomics, Inc.
Myriad Genetics, Inc.

第14章：發炎相關生物標記市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢
精準免疫學和基於生物標記的醫學的發展
未來，利用多體學和人工智慧的生物標記平台將廣泛應用。
長期市場展望及戰略意義

簡介目錄

Product Code: KSI-009077

The Inflammation-related Biomarkers Market is anticipated to grow at a CAGR of 10.7% from USD 7.44 billion in 2026 to USD 18.51 billion in 2035.

The inflammation-related biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision medicine and the growing recognition that chronic inflammation underlies numerous disease states. The market's evolution is characterized by the increasing demand for objective biological indicators capable of supporting diagnosis, prognosis, and treatment monitoring across diverse therapeutic areas, including autoimmune diseases, oncology, cardiovascular diseases, and infectious diseases. The convergence of advanced analytical platforms, including multiplex biomarker platforms, next-generation sequencing, and mass spectrometry, is enabling more comprehensive characterization of complex inflammatory pathways. Healthcare providers are seeking objective tools to evaluate disease activity and treatment effectiveness as the prevalence of autoimmune and chronic inflammatory diseases continues to rise. Pharmaceutical companies are increasing biomarker integration because therapeutic development requires measurable indicators of biological response. Regulatory agencies increasingly recognize inflammation-related biomarkers as critical tools supporting disease diagnosis, therapeutic development, and precision medicine strategies. The market is witnessing significant investment in multi-omics approaches, cytokine profiling, and AI-enabled biomarker discovery, positioning inflammation-related biomarkers as a core component of precision healthcare across global medical practice.

Market Drivers

The growing burden of autoimmune and chronic inflammatory diseases represents the primary driver for the inflammation-related biomarkers market. Autoimmune and chronic inflammatory diseases represent major healthcare challenges because persistent inflammation contributes to disease progression and long-term complications. Demand for inflammation-related biomarkers is increasing as healthcare providers seek objective methods for evaluating disease activity and treatment effectiveness. This requirement creates pressure on diagnostics developers to improve biomarker sensitivity and clinical relevance. Industry participants are expanding biomarker development programs to address evolving clinical needs. The outcome is stronger adoption of inflammatory biomarker testing across healthcare systems, resulting in sustained growth in inflammation-related biomarker utilization. The expansion of precision medicine and targeted therapies is further accelerating market growth through demand for biological characterization. Precision medicine relies on biological indicators that support individualized treatment decisions. Demand for inflammation biomarkers is rising because healthcare providers increasingly require patient-specific information regarding immune activity and therapeutic responsiveness. This trend exposes limitations associated with generalized treatment approaches that fail to account for biological variability. Organizations are strengthening biomarker research and validation efforts to improve personalized healthcare delivery. The result is broader integration of biomarker-guided treatment strategies. The increasing use of biomarkers in drug development is driving expansion of biomarker utilization across pharmaceutical research. Drug development depends on measurable biological endpoints that demonstrate treatment effectiveness and mechanism engagement. Demand for inflammation-related biomarkers is increasing as pharmaceutical companies seek earlier indicators of therapeutic response and patient stratification. This challenge increases the importance of biomarkers that support clinical trial efficiency and regulatory submissions. Organizations are incorporating inflammatory biomarkers into development programs to improve decision-making throughout the drug lifecycle. Advancements in multiplex and multi-omics technologies are accelerating market development through scientific advancement. Modern biomarker discovery requires technologies capable of evaluating complex biological interactions. Demand for advanced analytical platforms is increasing because inflammatory pathways involve multiple interconnected cellular and molecular mechanisms.

Market Restraints

Biomarker validation remains challenging because inflammatory responses vary significantly across patients, diseases, and clinical settings. The biological variability of inflammation creates challenges for consistent biomarker interpretation. Standardization limitations persist because testing methodologies and analytical platforms differ across laboratories and healthcare systems. The lack of harmonized protocols reduces comparability and clinical confidence. High implementation costs associated with advanced molecular and multiplex technologies continue limiting adoption in resource-constrained settings. The significant financial investment required for advanced platforms creates barriers for smaller facilities. Data integration and interpretation challenges create additional complexity for multi-parameter biomarker analysis.

Technology and Biomarker Type Insights

The technology landscape is characterized by the growing importance of multiplex biomarker platforms and integrated multi-omics approaches. Demand for multiplex biomarker platforms is increasing because inflammatory diseases involve numerous interconnected biological mediators that cannot be adequately characterized through single-marker approaches. This complexity strengthens the role of immunoassays, flow cytometry, PCR, and NGS technologies capable of generating multidimensional biological insights. Immunoassays remain essential for targeted protein biomarker measurement. Mass spectrometry is gaining adoption for comprehensive proteomic profiling. The segment analysis reveals that demand is shifting toward cytokine and chemokine biomarkers because immune-mediated diseases increasingly require dynamic evaluation of inflammatory signaling pathways. Acute phase protein biomarkers, including CRP, continue supporting routine clinical assessment of inflammation. Cellular inflammatory biomarkers provide insight into immune cell involvement. Genetic and genomic inflammatory biomarkers are expanding for patient stratification and precision medicine. Multi-biomarker panels are gaining adoption because inflammatory pathways involve multiple interconnected biological signals. Autoimmune diseases represent a major application because treatment decisions increasingly depend on biological characterization of immune activity. Oncology, cardiovascular diseases, infectious diseases, neurological disorders, and metabolic disorders represent significant and growing application areas. Hospitals and clinical laboratories represent the leading end-user segment, with pharmaceutical and biotechnology companies expanding biomarker utilization. The integration of AI is becoming increasingly important because inflammatory biomarker research generates complex datasets requiring advanced analytical capabilities. Organizations are incorporating machine learning technologies to improve biomarker discovery and clinical interpretation.

Competitive and Strategic Outlook

The competitive landscape features established life science and diagnostics companies alongside specialized biomarker, analytics, and precision medicine providers. Thermo Fisher Scientific maintains a leading position because its broad portfolio of analytical instruments, immunoassays, molecular biology tools, and translational research solutions supports the entire biomarker development workflow, expanding integrated research and diagnostics capabilities to address growing complexity in biomarker discovery and validation. Roche differentiates itself through the combination of pharmaceutical development, companion diagnostics, and precision medicine initiatives, expanding biomarker-enabled healthcare programs across immunology, oncology, and chronic disease management applications. Danaher occupies a significant position because its operating companies provide technologies that support biomarker discovery, molecular analysis, and translational research, strengthening innovation through continued investment in diagnostics and life sciences capabilities. Bio-Rad remains an important participant because its technologies support assay development, biomarker quantification, and translational research activities, expanding analytical capabilities through continuous technology enhancement and workflow optimization initiatives. QIAGEN maintains strategic importance because molecular diagnostics and sample analysis technologies continue supporting biomarker-driven healthcare approaches, expanding molecular analysis capabilities to address growing requirements within precision medicine and translational research. Agilent supports the market through analytical technologies that enable biomarker characterization and metabolomic, proteomic, and genomic investigations, strengthening innovation efforts to improve analytical performance and research efficiency. Illumina differentiates itself through leadership in sequencing technologies that support genomic and transcriptomic biomarker discovery. Companies are pursuing product portfolio expansion through innovation in multiplex biomarker panels, multi-omics platforms, and AI-enabled discovery tools. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for biomarker discovery and validation. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The inflammation-related biomarkers market is positioned for sustained growth driven by the convergence of chronic disease burden, precision medicine, and technological innovation. The transition from isolated biomarker measurements toward integrated multi-omics and multiplex platforms represents a fundamental shift in precision healthcare. While challenges related to biomarker validation, standardization, and implementation costs persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with inflammation-related biomarkers evolving from a research-centered field into a core component of precision healthcare, supporting diagnosis, treatment optimization, and therapeutic development across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Inflammation-related Biomarkers Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Disease Burden and Unmet Clinical Needs
3.8 Epidemiology and Prevalence Analysis of Inflammation-Associated Disorders
3.9 Diagnosed Patient Population Analysis
3.10 Testing Volume Analysis
3.11 Biomarker Utilization Across Clinical and Research Applications
3.12 Inflammation Biomarker Role in Precision Medicine

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Biomarker Discovery Technologies
6.2 Product Innovation and Assay Development
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Multi-omics Integration in Biomarker Research
6.6 AI-Enabled Biomarker Identification and Validation
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Inflammation-related Biomarkers Market Landscape Analysis

8.1 Analysis by Biomarker Type
8.2 Analysis by Technology Platform
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology

9. Inflammation-related Biomarkers Market Segment Analysis (2021-2035)

9.1 By Biomarker Type
- 9.1.1 Cytokine Biomarkers
- 9.1.2 Chemokine Biomarkers
- 9.1.3 Acute Phase Protein Biomarkers
- 9.1.4 Cellular Inflammatory Biomarkers
- 9.1.5 Genetic and Genomic Inflammatory Biomarkers
- 9.1.6 Multi-biomarker Panels
9.2 By Technology Platform
- 9.2.1 Immunoassays
- 9.2.2 Flow Cytometry
- 9.2.3 Polymerase Chain Reaction (PCR)
- 9.2.4 Next-Generation Sequencing (NGS)
- 9.2.5 Mass Spectrometry
- 9.2.6 Multiplex Biomarker Platforms
9.3 By Clinical Application
- 9.3.1 Autoimmune Diseases
- 9.3.2 Oncology
- 9.3.3 Cardiovascular Diseases
- 9.3.4 Infectious Diseases
- 9.3.5 Neurological Disorders
- 9.3.6 Metabolic Disorders
9.4 By End User
- 9.4.1 Hospitals and Clinical Laboratories
- 9.4.2 Academic and Research Institutes
- 9.4.3 Pharmaceutical and Biotechnology Companies
- 9.4.4 Contract Research Organizations